Objective:To obtain human S100A2-GST fusion protein for further research on human S100A2(hS100A2)protein function and its interactions with other proteins and systems.Methods:hS100A2 gene from pHAHA-hS100A2 was subcloned into an expression vector pGST-moluc to construct pGST-moluc-hS100A2.The new plasmid was identified by digestion with XhoⅠand EcoRⅠ.The recombinant BL21 was induced with IPTG to express recombinant fusion protein hS100A2-GST,which was purified by Glutathion-Sepharose 4B ball beads,identified by SDS-PAGE and Western Blot,and quantified by Bradford method.Results:After the digestion,the recombinant plasmid was cutted into two fragments,300 bp and 5kb.After treated with IPTG,the recombinant BL21 strain expressed a protein,which was about 36 kD and was recognized specifically by an-ti-hS100A2.Its yield was 5 mg/L bacterial culture.After isolated by Glutathion-Sepharose 4B ball beads,its purity was 92%.Conclusion:hS100A2-GST expression plasmid pGST-moluc-hS100A2 was constructed successfully.hS100A2-GST fusion pro-tein could be expressed in Escherichia coli with higher yield and isolated with higher purity,which lays the foundation for the follow-up of the hS100A2 research.

Objective To explore the effect and safety of the regimen containing Moxifloxacin in intensive phase for pulmonary tuberculosis patients. Methods 88 cases with initial tuberculosis(each group of 44 cases) were studied in comparison in the same period. The treatment group contained isoniazid, rifampicin and moxifloxacin of antituberculosis regime and the control group contained isoniazid,rifampicin and pyrazineamide. Results After 2 months intensive phase anti-tubercular treatment ,the sputum negative conversion rates was 95.0% and control's was 94.4%(P ＞ 0.05); the absorb rate of lesions: the treatment group 77.3 % and the control group 79.5%; the liver damage rate: the treatment group and control group was 68.2% ,34.1% respectively(P ＜ 0.05). Conclusion Anti-tuberculosis intensive phase regimes containing moxifloxacin for tuberculosis treatment was safe and effective in initial treatment of pulmonary tuberculose.

OBJECTIVE:To compare the contents of Rhodioloside and polysaccharide extracted from different part in cultivated Rhodiola sachalinensis.METHODS:The Rhodioloside was extracted with 70% alcohol and determined by HPLC;The polysaccharide was extracted with water and determined by sulphuric acid-phenol method.RESULTS:The content of the Rhodioside ranged between 0.026 5% and 0.443 2%,and the content of polysaccharide between 0.965% and 4.612% in the medicinal herbs,with the main root showing the highest contents.CONCLUSION:The contents of Rhodioside and polysaccharide are obviously different in different part of cultivated Rhodiola sachalinensis.The results provided reasonable theoretical evidence for the exploitation of cultivated Rhodiola sachalinensis.

0.05). The patients whose Pre-S2 antigen and antibody are positive in the serum are mainly with chronic hepatitis B (P

As a member of GTPase Rab family,Rab10 protein is not only involved in vesicle formation,transport,anchoring and fusion process,but also affects the occurrence and development of tumors.Research about the mechanisms of Rab10 in intracellular vesicle transport and tumor may provide a potential target and new idea for the anti-cancer therapy.

Objective:To analyze the causes and countermeasures for the inefficiency of implementing the contract community health service policy.Methods:Based on the authority and regulation of organization,it innovatively used the French organization theory,build an analysis framework of organizational actors adapting to the general organization.On the above basis combined with the characteristics of contract health service,it constructed a new organizational structure of contract health service and analyzed the low efficiency of policy implementation from the three relations among the actors,the power and the rule.Results and Conclusion:It needed to focus on authority and rule to rationally division the authorities of actors,optimize the organizational structure,adjust the benefit relationship of actors;play the regulation role,implement the incentive and constraint mechanism to improve the execution efficiency of contract health service policy.

Objective:To prepare nevirapine nanosuspensions ( Nev-NS) and study the pharmacokinetics in rats. Methods:Nev-NS was prepared by a high pressure homogenization technology. The particle size, PDI and Zeta potential of the nanosuspensions were used as the indices to determine the influencing factors in the preparation process. Nevirapine plasma concentration was detected by HPLC and the pharmacokinetic parameters were calculated by 3P97 software. Results: The particle size, PDI and Zeta potential of Nev-NS was (456. 1 ± 72. 1) nm, 0. 441 ± 0. 072 and ( -24. 4 ± 4. 7) mV, respectively. AUC0-12 of Nev and Nev-NS was (7. 57 ± 0.52) and (11.72 ±1.83) mg·h·L-1, t1/2 was (2.45 ±0.31) and (3.16 ±0.39) h, Tmax was (1.43 ±0.38) and (1.61 ± 0. 32) h and Cmax was (1. 62 ± 0. 42) and (3. 15 ± 0. 52) mg·L-1 , respectively. Conclusion:Nev-NS can improve the pharmacoki-netic behavior of Nev in rats significantly, and obviously enhance the bioavailability when compared with nevirapine suspensions.

Objective]To study Xin'an physician Wu Cheng asthenic diseases related theory of ideas in Bujuji, in order to more comprehensively understand asthenic diseases,to broaden the thinking, enhance the clinical curative effect. [Method]From the academic source of asthenic diseases , syndrome differentiation and treatment,prescription medication,clinical academic value, make research on Wu's thought about asthenic diseases treatment. [Result]Wu Cheng combined with their own perception and experience of clinical evidence, first put forward“external damage caused by asthenic diseases”;Aiming at the asthenic diseases of the treatment,Wu Cheng creatively put forward“support solution method”, “supplementary care method”, “treatment of spleen yin”;Wu Cheng's life was exploring the asthenic diseases,the theory of asthenic diseases had good clinical academic value,not only for the development of the cause of disease theory,but also enriching the theory of health prevention.[Conclusion]Wu Cheng Bujuji rich in content and its syndrome differentiation of asthenic diseases, with much experience, as today, treatment based on the thought of clinical asthenic diseases treatment still has important guiding significance.

Objective To explore the measures in early diagnosis and treatment for venous thromboembolism(VTE)in patients with fracture.Methods All the patients with fracture visiting Beijing Jishuitan Hospital in emergency during October 2004 to October 2007 were screened by Well's prediction rules,and anticoagulation and thrombolysis were instituted for those with established diagnosis of VTE by color Doppler ultrasonography and venography.Results Totally,1 508 patients at higg-risk of VTE were identified by D-dimer test.1 455 by color ultrasonography and 53 by venography.Diagnosis of VTE was established in 652 of them(43.2%),619(94.9%)received anticoagulant treatment,162(24.8%)received anticoagulant plus thrombolytie treatment and 25 (3.8%) received anticoagulation plus thrombectomy.In order to prevent fatal pulmonary embolism,vena cava filters(VCFs)were implanted in 146(22.4%)patients,and 33(5.1%)of them were contraindicated to anticoagulation.After treatment,412 cases were cured and 240 were improved,with no one failed.Conclusions Patients with fracture are at high-risk of VTE and should be screened by D-dimer test and color Doppler ultrasonography based on Well's evaluation,as well as by venography for confirming the diagnosis of VTF as appropriate.Anticoagulation and thrombolysis are still the treatment of choice,with thrombectomy and VCF implantation performed only if necessary.

Many studies have shown that the embolism caused by vulnerable atherosclerotic plaque is one of the major causes of ischemic stroke. However, there is still not a simple and precise method to identify the vulnerable plaques yet. This article reviews the various methods for detecting vulnerable plaques from the aspects of serology and imaging.